X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Research And Views Archives | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Archives... Don't Miss Anything, Ever!

Here you will find all the research and views that we post on Equitymaster. Use the tools to customize the results to suit your preference!
















Authors
 

A drug where Ranbaxy scores over Dr Reddy's

(Jul 5, 2013)

Equitymaster explains, which company is better of in the Isotretinoin drug in US.

Dr.Reddy's vs. Teva: Which generics co. is better?

(Jan 7, 2011)

Equitymaster compares the largest generics company in the world, the Israeli based Teva with India's Dr.Reddy's

Pharma: Hiving off R&D...

(Sep 4, 2007)

The introduction of the product patent law in the country has compelled domestic pharma companies to increase their focus on R&D - to counter the likely slowdown of reverse engineered products in the future.

Dr. Reddy's: Will it recover?

(Jun 1, 2005)

Dr. Reddy's Laboratories is a leading pharmaceutical company in the country, having a presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, biotechnology and diagnostics. The company has filed 64 patents till now and is the first from India to get an Exclusive Marketing Right (EMR) in the US market for Fluoxetine Axetil. The company exports bulk drugs, branded and generic formulations to over 60 countries. Active Pharmaceutical ingredients (AP

Pharma R&D: Worth investing!

(Jan 6, 2005)

R&D is increasingly becoming an area of focus for Indian pharma companies and most of the big players are spending about 6%-7% of their revenues on R&D activity. While this is much lower when compared to the amount spent by global pharma majors (around 12%-15% of revenues), it must be noted that since Indian companies are operating at the lower end of the value chain, they cannot afford higher R&D expenses.

Dr Reddy’s: A volatile story

(Dec 9, 2004)

Dr Reddy’s has been one of the most revered domestic pharmaceutical companies. The reverence for the company is due to its vision to be a research driven company and the company has been valued more than any other in the Indian pharma sector. Dr Reddy’s has been one of the first few companies in the country to enter in NCE (new chemical entity) research and spending a large proportion of its revenue on the same. Despite these positives, the stock of the company has been ‘hammered’ in recent time

Dr Reddy's: Yet another disappointment

(Oct 27, 2004)

Domestic pharmaceutical major, Dr. Reddy’s, has declared its 2QFY05 results. The topline of the company has grown marginally, owing to poor sales in generics and bulk drug segments. The bottomline of the company is lower by 48% due to very high increase in operational expenses, depreciation and interest outgo.

Dr Reddy's: Dismal performance

(May 29, 2004)

Dr Reddy's announced poor March quarter and FY04 results yesterday. The net sales of the company were down 1.4% in 4QFY04, while net profit was down by 91% on a standalone basis. The company incurred operating loss of Rs 195 m. The performance for the full year too, was not very encouraging, with net profit plummeting by 29% to Rs 2,830 m. Although revenues of the company in FY04 were up 9%, the operating profit of the company fell by 33% YoY. The operating margins plummeted to 18% compared to 2

Pharma industry: Year 2005 and beyond

(Feb 27, 2004)

The year 2005 is likely to be a turning point for India Inc. in general, and the pharma industry in particular. This is in light of the fact that the new patent regime instituted by the WTO will come into force from January 1, 2005. Process patents, which are recognized in India and many other developing countries at present, will have to make way for product patents. Let us understand what would be the likely impact of this new patent regime on the Indian pharmaceutical industry.

Dr Reddy’s: Lacking growth drivers

(Oct 28, 2003)

Domestic pharma major, Dr Reddy’s Laboratories (DRL) has announced its 2QFY04 results. On a standalone basis, DRL has reported an 11% increase in topline and a 5% rise in bottomline. While the bulk drugs and formulations business saw modest growth, the generics and diagnostics businesses acted as dampeners. On a consolidated basis, while the group has reported a 13% rise in net sales, net profit has dropped by 15%. In this context, let us undertake a detailed review of the company’s performance

Pharma: Beyond 2005

(Aug 21, 2003)

The pharma stocks are off late having a dream run on the bourses. Most of the stocks have breached their 52-week high levels, while others are on the verge of crossing the same. The rally has been across the board and even the mid-cap stocks have benefited.

Dr. Reddy’s: Consolidation woes

(Aug 5, 2003)

Domestic pharma major, Dr. Reddy's Laboratories (DRL) has recorded healthy growth in 1QFY04. While the topline increased by 30%, the bottomline grew by a strong 54%. However, on a consolidated basis, DRL has reported a meager 7% increase in total revenues and a 34% dip in net profits.

Dr. Reddy’s Vs Ranbaxy Vs Teva

(Jun 27, 2003)

‘Generics’ has been the buzzword among Indian pharma majors for some time now, and not without reason. There exists significant potential for generics manufacturers in the regulated markets. Two Indian generics majors, Ranbaxy and Dr. Reddy’s (DRL), have been increasingly focusing on this market for sustained growth. But what would the future hold for companies that follow this business strategy? To get

Dr. Reddy's: Strength despite generic hiccups

(Jun 10, 2003)

Pharma major, Dr. Reddy's reported its FY03 annual results recently. The article is a behind the scenes look at the company's financials, both standalone and consolidated.

Dr. Reddy: 2Q PAT down 31%

(Oct 24, 2002)

Dr. Reddy's, after reporting solid growth over the past year, has registered a decline in turnover. The drop in sales is primarily due to slowdown in fluoxetine sales, which has reflected across the income statement. The company has continued to show good growth in active pharma ingredients (API) business and branded formulations.

Cipla: Omeprazole disappointment

(Oct 14, 2002)

In a big disappointment for Cipla, Andrx the US partner of the company has lost its patent challenge for generic Omeprazole (Prilosec). The US district court has ruled that Andrx infringes the original patent of AstraZeneca. Since Cipla was expected to supply a major part of Andrx’s raw material requirement for Omeprazole, market participants were expecting major revenues from this bulk exports.

Who’s the fairest of them all?

(Sep 14, 2002)

Valuations of the Indian pharma sector have undergone a sea change in the last couple of years. MNC pharma companies, once darling on the bourses, went out of favour with investors in mid-1999 as better growth opportunities became visible for Indian pharma majors.

Dr. Reddy's: Outstanding performance

(Aug 1, 2002)

Dr. Reddy's has reported an outstanding all round performance for the first quarter of FY03. Continued buoyancy in sales coupled with improving margins have led to strong earnings growth for the company. Dr.Reddy's has disclosed global consolidated revenues as per US GAAP. On a consolidated basis, the company reported a stupendeous 115% rise in net profits and a 51% growth in revenues on the back of strong growth in API's (Active Pharma Ingredients) and continued progress in the generics busines

Anti-Diabetes: An upshot

(Jul 27, 2002)

Diabetes is one of the fastest growing epidemics globally. Statistics rolled out by World Health Organisation predicts that globally people suffering from this aliment would double to 300 m by 2025. Incidentally, India has one of the fastest growing diabetes patient’s worldwide, thanks to rapid expansion of urbanization and consequent stress levels.

Dr. Reddy’s: Ground realities

(Jul 27, 2002)

Early during the week, Dr. Reddy’s stock fell more than 16% in the intra day movement. This was in reaction to the suspension of clinical trials for its anti-diabetic molecule licensed to Novo Nordisk. This came as a major setback for the company. DRF-2725, the dual acting insulin sensitiser termed as ‘Ragaglitazar’ was amongst the major catalyst for the company’s research efforts.


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MARKET STATS